1. Considered and approved the Audited Financial Results for the fourth quarter and Financial Year Ended 31st March, 2025. The said Audited Financial Results were reviewed by the Audit ....

Revenue growth above 20%Net loss reportedExceptional itemEBITDA margin compressionDebt to equity above the thresholdResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.9%Reaction day

₹95.15

prior close

₹91.01

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.1%+1.9% vs market

Pharmaceuticals peers, median of 147sector-0.1%+2.1% vs sector

On the reaction day the stock moved 1.9 pts more than Nifty Microcap 250 and 2.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.0

10m

+1.6

15m

+3.8

30m

+3.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.9+0.1+1.9-0.1+2.1

Next day

+0.9-0.2+1.1-0.3+1.2

+3.0+0.3+2.7-0.3+3.3

+14.3+0.9+13.4+0.0+14.3

+31.4+0.8+30.6+0.0+31.4

+31.0+2.2+28.8+0.6+30.4

+30.3+3.4+26.9+1.4+28.9

15d

+28.2-0.8+29.0-3.0+31.3

+23.0+2.9+20.0+0.2+22.8

+3.7+0.8+2.8-0.5+4.2

-24.5+0.0-24.5-3.2-21.2

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 147Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Oxygenta Pharmaceutical's board approved audited financial results for Q4 and FY ended March 31, 2025, along with shifting of its corporate office within Hyderabad (from Gachibowli to Kukatpally). Revenue from operations jumped nearly threefold to Rs 10,929.86 lakhs in FY25 from Rs 3,964.21 lakhs in FY24, a growth of about 175%. However, the net loss widened sharply to Rs 1,029.83 lakhs versus Rs 347.93 lakhs in the previous year. Q4 FY25 also posted a loss of Rs 215.29 lakhs. The statutory auditor (A.M Reddy & D.R Reddy) issued an unmodified (clean) opinion on the results. The company reported negative other equity of Rs 6,262.40 lakhs, indicating eroded net worth, and total borrowings of Rs 6,223.24 lakhs.

Likely market impact

Strong revenue growth is a positive, but deepening losses and negative net worth raise concerns about the company's financial health and sustainability. Shareholders should watch whether the topline growth translates into profitability going forward; near-term stock reaction may be cautious given the widened losses and weak balance sheet despite the clean auditor opinion.